- Home
- NVEI vs CRSP Comparison
NVEI vs CRSP Comparison
Compare NVEI & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVEI
- CRSP
- Stock Information
- Founded
- NVEI 2003
- CRSP 2013
- Country
- NVEI Canada
- CRSP Switzerland
- Employees
- NVEI N/A
- CRSP N/A
- Industry
- NVEI
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NVEI
- CRSP Health Care
- Exchange
- NVEI Nasdaq
- CRSP Nasdaq
- Market Cap
- NVEI 4.7B
- CRSP 4.0B
- IPO Year
- NVEI 2021
- CRSP 2016
- Fundamental
- Price
- NVEI $33.99
- CRSP $47.25
- Analyst Decision
- NVEI Hold
- CRSP Buy
- Analyst Count
- NVEI 14
- CRSP 19
- Target Price
- NVEI $32.38
- CRSP $73.69
- AVG Volume (30 Days)
- NVEI 1.1M
- CRSP 1.8M
- Earning Date
- NVEI 11-12-2024
- CRSP 11-05-2024
- Dividend Yield
- NVEI 1.18%
- CRSP N/A
- EPS Growth
- NVEI N/A
- CRSP N/A
- EPS
- NVEI 0.16
- CRSP N/A
- Revenue
- NVEI $1,359,722,000.00
- CRSP $202,829,000.00
- Revenue This Year
- NVEI $18.83
- CRSP N/A
- Revenue Next Year
- NVEI $15.63
- CRSP $526.27
- P/E Ratio
- NVEI $203.07
- CRSP N/A
- Revenue Growth
- NVEI 24.89
- CRSP 19.31
- 52 Week Low
- NVEI $19.07
- CRSP $43.42
- 52 Week High
- NVEI $34.00
- CRSP $91.10
- Technical
- Relative Strength Index (RSI)
- NVEI 72.51
- CRSP 44.94
- Support Level
- NVEI $33.42
- CRSP $50.60
- Resistance Level
- NVEI $33.70
- CRSP $59.07
- Average True Range (ATR)
- NVEI 0.13
- CRSP 2.84
- MACD
- NVEI 0.04
- CRSP -0.35
- Stochastic Oscillator
- NVEI 98.49
- CRSP 7.48
About NVEI Nuvei Corporation Subordinate Voting Shares
Nuvei Corp is a provider of payment technology solutions to merchants and partners. The solutions provided are mobile payments, online payments, and In-store payments. Its geographical segments are North America; Europe, the Middle East, and Africa; Latin America; and the Asia Pacific. The vast majority of the company's revenue is generated from North America and EMEA.
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for to treat Type 1 diabetes.